title: Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients.
abstract: We prospectively followed 70 CMV-seropositive solid organ transplant recipients to evaluate the efficacy and safety of valganciclovir (VGCV) as preemptive therapy based on antigenemia test to prevent cytomegalovirus (CMV) disease. From December 2003 to May 2004, 12 of 70 (17%) asymptomatic patients who showed an antigenemia value > or =25 positive cells per 2 x 10(5) polymorphonuclear (PMN) were treated with VGCV (900 mg twice a day adjusted to renal function) until resolution of CMV antigenemia, a minimum of 14 days. No patient developed CMV disease during follow-up. Only one who showed an asymptomatic relapse of the antigenemia test > or =25 positive cells was successfully treated with a repeated course of VGCV. Mean duration of VGCV therapy was 18 days (range, 14 to 28). Antigenemia was negative in 7 of 12 (58%) patients after 14 days and negative in all patients 4 weeks after the administration of VGCV. No significant side effects were associated with the use of VGCV therapy. Preemptive VGCV therapy is safe and effective in the prevention of CMV disease in seropositive solid organ transplant recipients.
authors.affiliation: Infectious Diseases Unit, Department of Digestive Surgery and Abdominal Organs Transplantation, University Hospital 12 de Octubre, Madrid, Spain. carmendiaz@ya.com
authors.forename: C
authors.initials: C
authors.lastname: Díaz-Pedroche
authors.forename: C
authors.initials: C
authors.lastname: Lumbreras
authors.forename: P
authors.initials: P
authors.lastname: Del Valle
authors.forename: R
authors.initials: R
authors.lastname: San Juan
authors.forename: S
authors.initials: S
authors.lastname: Hernando
authors.forename: D
authors.initials: D
authors.lastname: Folgueira
authors.forename: A
authors.initials: A
authors.lastname: Andrés
authors.forename: J
authors.initials: J
authors.lastname: Delgado
authors.forename: J C
authors.initials: JC
authors.lastname: Meneu
authors.forename: J M
authors.initials: JM
authors.lastname: Morales
authors.forename: E
authors.initials: E
authors.lastname: Moreno
authors.forename: J M
authors.initials: JM
authors.lastname: Aguado
mesh_terms: D000956:Antigens, Viral / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000302:isolation & purification; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016027:Heart Transplantation; D006801:Humans; D016030:Kidney Transplantation; D016031:Liver Transplantation; D011183:Postoperative Complications / Q000517:prevention & control* / Q000821:virology; D000077562:Valganciclovir
chemical_list: D000956:Antigens, Viral; D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir